Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Grifols, S.A.

SG&A Cost Optimization: Regeneron vs. Grifols

__timestampGrifols, S.A.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014660772000504755000
Thursday, January 1, 2015736435000838526000
Friday, January 1, 20167752660001177697000
Sunday, January 1, 20178603480001320433000
Monday, January 1, 20188147750001556200000
Tuesday, January 1, 20199428210001834800000
Wednesday, January 1, 20209856160001346000000
Friday, January 1, 202110615080001824900000
Saturday, January 1, 202211904230002115900000
Sunday, January 1, 202312542340002631300000
Monday, January 1, 20242954400000
Loading chart...

Cracking the code

Optimizing SG&A Costs: A Tale of Two Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Grifols, S.A. have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Regeneron has seen a significant increase in SG&A expenses, rising by over 420%, from approximately $505 million to $2.63 billion. In contrast, Grifols has managed a more modest increase of around 90%, from $661 million to $1.25 billion.

This divergence highlights Regeneron's aggressive expansion and investment in administrative capabilities, while Grifols appears to focus on cost efficiency. As the pharmaceutical landscape evolves, these strategies will play a pivotal role in shaping each company's financial health and market position. Investors and industry analysts should closely monitor these trends to gauge future performance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025